Through its partnership with the Sarah Cannon Research Institute, FCS conducts community-based clinical trials to support the development of new oncology treatments.
Impact on McKesson’s Oncology Network
Following the acquisition, FCS will remain independently owned and will join McKesson’s US Oncology Network, a platform focused on expanding local and affordable cancer care. Core Ventures will be integrated into McKesson’s oncology services, furthering McKesson’s reach in cancer care.
“This is a historic moment for FCS,” said FCS CEO Nathan H. Walcker, highlighting the shared mission between FCS and the US Oncology Network to strengthen community-centered cancer care. “We are thrilled to partner with McKesson and join the Network.”
McKesson $2.49B Deal For Cancer Biz : Legal Representation
FCS is being represented by a team from Paul Weiss Rifkind Wharton & Garrison LLP, including partners Krishna Veeraraghavan and Cullen L. Sinclair. Counsel for McKesson was not immediately available at the time of the announcement.
